Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD

NCT03135054 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

AML
FLT3-ITD Mutation

Interventions

DRUG: Quizartinib
DRUG: Omacetaxine Mepesuccinate Injection

Sponsor

The University of Hong Kong